Ganciclovir susceptibilities and UL97 sequences were analyzed in 20 cytomegalovirus (CMV) isolates recovered from 15 bone marrow transplant recipients with active CMV infection after prophylaxis with acyclovir (group I; 12 isolates) or after acyclovir prophylaxis followed by ganciclovir therapy (group II; 8 isolates). All group I isolates were susceptible to ganciclovir. Five group II isolates were susceptible to ganciclovir, and 3 isolates (all from the same person) were resistant to ganciclovir (IC 50 ú12 mM). Ganciclovir resistance UL97 mutations were found in 4 group II isolates, including a ganciclovir-susceptible isolate obtained from 1 patient after 41 days of therapy with ganciclovir and 3 ganciclovir-resistant isolates obtained from another patient after 73, 116, and 132 days of treatment with ganciclovir. Ganciclovir-resistant CMV isolates may emerge rapidly in bone marrow transplant recipients who are treated with ganciclovir after receiving prophylaxis with acyclovir.
Cytomegalovirus (CMV) is a major pathogen for bone mar-
In these clinical isolates, resistance to ganciclovir has been related to UL97 mutations at one or several loci [8, 9] . row transplant recipients, in whom it causes severe complications including hepatitis, gastrointestinal disease, and interstiBecause acyclovir shares the same mechanism of activation and action as ganciclovir against CMV, it is theoretically possitial pneumonitis [1] . Advances have been made in the prevention of CMV disease after bone marrow transplantation, ble for UL97 mutations causing resistance to ganciclovir to occur under selective pressure during exposure to acyclovir. including prophylactic administration of antivirals such as acyclovir and ganciclovir [2, 3] . These two compounds are
To test this hypothesis, we analyzed ganciclovir susceptibilities and UL97 sequences of CMV isolates recovered from bone nucleoside analogues that must be phosphorylated to their nucleotide form (triphosphate) to inhibit the viral DNA polymermarrow transplant recipients who developed active CMV infection after receiving prophylaxis with acyclovir. ase. The initial phosphorylation of acyclovir and ganciclovir to their monophosphates is mediated by a protein kinase encoded by the UL97 gene of CMV [4, 5] .
Materials and Methods CMV prophylaxis with antivirals in the context of bone marrow transplantation is administered for prolonged periods CMV isolates. Viruses studied were selected among those of time. A potential risk associated with prolonged use of antiavailable at the University of Minnesota Clinical Virology Laboravirals is the emergence of resistant viruses. Specifically, CMV tory from bone marrow transplant recipients who developed active isolates resistant to ganciclovir have been recovered from im-CMV infection after receiving prophylaxis with acyclovir (10 mg/ kg intravenously [iv] every 8 h starting from up to 10 days before munocompromised patients treated with this compound [6, 7] . transplantation to 30 days afterward, followed by 800 mg orally 5 times per day for the first 100 days after transplantation). Patients treated with ganciclovir received 5 mg/kg iv every 12 h for 14 isolates with ganciclovir IC 50 s ú6 mM were considered resistant. 418-702 of UL97 were obtained by polymerase chain reaction strain AD169. Primer sequences were 5-CATCGACGTTTCanalysis in all isolates (table 1). Of note is that the S510 muta-CACACAGAC-3 (Z2671, forward) and 5-CCTCAGCAACCGtion had a restriction pattern similar to that of the Q520 muta-TCACGTTC-3 (Z2992, reverse). Amplified products were setion (figure 1).
quenced by a commercial kit (Prism Ready Reaction Dyedeoxy Terminator Cycle Sequencing kit; Applied Biosystems, Foster City, CA) and primers Z2671 and Z2992. An additional pair of Discussion internal sequencing primers, 5-GCACCGTCTGCGCGAATGOur study suggests that CMV isolates containing UL97 mu-TTA-3 (Z6813, forward) and 5-AGATGAGCAGCTTCTGCAtations associated with resistance to ganciclovir may emerge GCG-3 (Z1600, reverse), was used to generate complete UL97 in bone marrow transplant recipients who are treated with gansequences. UL97 sequences were aligned with existing sequence ciclovir after receiving prophylaxis with acyclovir. The UL97 data to detect previously described drug resistance mutations.
Screening (IC 50 of ú98 mM in a cytopathic effect reduction assay) were recovered from the blood and bronchoalveolar lavage fluid of a patient treated with ganciclovir for ú2 months [11] . In a Results survey by the European Group for Blood and Bone Marrow Transplantation, 23 patients with ganciclovir-resistant CMV Patients and virus isolates. Twenty CMV isolates from 15 bone marrow recipients were included in the study. All patients infections were reported from 19 of the 68 participating centers [12] . However, resistance to ganciclovir was documented in had active CMV infections. Isolates were recovered from patients after prophylaxis with acyclovir (group I; 12 isolates) or after only 2 cases. In another study [13] , a ganciclovir-resistant CMV isolate (IC 50 of 14.5 mM in a DNA hybridization assay) was acyclovir prophylaxis followed by ganciclovir therapy (group II; 8 isolates). CMV isolates from group I were obtained after an recovered from a lung autopsy sample in a bone marrow transplant recipient with a second episode of CMV pneumonitis average of 58 days (range, 23-118) of acyclovir prophylaxis. CMV isolates from group II were obtained after an average of who had received acyclovir prophylaxis and two courses of ganciclovir therapy for a total of 55 days. 46 days (range, 34-76) of acyclovir prophylaxis and of 69 days (range, 9-132) of ganciclovir therapy. Clinical data and results
An interesting finding in our study was the rapid emergence of viruses containing ganciclovir resistance UL97 mutations in of virologic studies are summarized in table 1.
Ganciclovir susceptibilities. All 12 group I isolates were suspatients who received acyclovir prior to ganciclovir as prophylaxis. Specifically, isolates 12A and 15B were recovered after ceptible to ganciclovir, with a mean IC 50 of 1.6 mM (range, 0.5-4). Five of 8 group II isolates were susceptible to ganciclovir, 41 and 73 days of ganciclovir therapy (table 1) . This contrasts with results of a previous study, in which ganciclovir-resistant with a mean IC 50 of 3.5 mM (range, 1.4-5.1). The 3 resistant isolates in this group (all obtained from the same subject) had CMV isolates were recovered from the urine of patients with AIDS after an average of 6.7 months of ganciclovir therapy IC 50 s of 12.2 to ú25 mM. The mean ganciclovir IC 50 of the susceptible control AD169 was 2.1 mM (range, 1.2-4.7).
[7]. Because genetic analysis of the isolates was not done in that study, the possibility that earlier susceptible isolates could Analysis of CMV UL97. Five group I isolates contained UL97 mutations, including 2 isolates with a Gln-to-Lys mutacontain UL97 mutations cannot be excluded. Whether prior exposure to acyclovir selects ganciclovir-retion at codon 449 (K449 mutation), 2 isolates with an Asn-toSer mutation at codon 510 (S510 mutation), and 1 isolate with sistant CMV isolates is not clear. In our initial study of ganciclovir resistance [6], a ganciclovir-resistant isolate (IC 50 of a His-to-Tyr mutation at codon 469 (Y469 mutation). Four of the 5 group II isolates that were susceptible to ganciclovir 14.4 mM in a plaque-reduction assay) was recovered prior to ganciclovir therapy from a patient with chronic leukemia who contained UL97 mutations, including a Y469 mutation (1 isolate), an S510 mutation (2 isolates), and a V594 mutation (1 had been treated intermittently with iv acyclovir. This isolate contained a V594 mutation in UL97 [10] . In another study, a isolate). The 3 remaining group II isolates (15B, 15C, 15D) were resistant to ganciclovir. Isolate 15B contained an Ala-to-CMV isolate with reduced susceptibility to ganciclovir (IC 50 of 7.1 mM in a plaque-reduction assay) was recovered from a Val mutation at codon 594 (V594 mutation); isolate 15C had a His-to-Gln mutation at codon 520 (Q520 mutation); and isosolid organ transplant recipient after a 14-day course of treatment with acyclovir [14] . Other studies have suggested that late 15D had both mutations.
Restriction digest analysis of UL97. Results of restriction antiviral prophylaxis does not result in the selection of resistant CMV isolates. For instance, none of 6 urine CMV isolates digest analysis for the most common ganciclovir resistance UL97 mutations were concordant with results of sequencing recovered from 6 patients with AIDS treated with acyclovir / 9d4c$$au49 07-01-98 22:03:35 jinfa UC: J Infect NOTE. BAL Å bronchoalveolar lavage fluid; ACV Å acyclovir; GCV Å ganciclovir; wt Å wild type sequence; D Å mutation present at indicated codon; Neg Å no mutation detected. * This patient had CMV pneumonia (documented by biopsy) and completed 42-day course of GCV therapy before bone marrow transplantation.
for an average of 15 months were resistant to ganciclovir [15] . In a study by our group, none of 17 CMV isolates from solid organ transplant recipients who developed active CMV infections after receiving prophylaxis with acyclovir were resistant to ganciclovir [16] . However, these results were based on ganciclovir susceptibility testing alone. These isolates are currently being analyzed to determine whether any of the viruses contain ganciclovir resistance UL97 mutations. In the current study, all CMV isolates from patients who had received only acyclovir prophylaxis were susceptible to ganciclovir, but analysis of UL97 revealed the presence of mutations (K449, Y469, S510) in 5 of the isolates. In a previous report [8] , a Gln-to-Arg mutation at UL97 codon 449 (R449 mutation) was found in 11 ganciclovir-susceptible isolates and 1 ganciclovir-resistant isolate, and the Y469 mutation was found in a ganciclovir-susceptible isolate and a ganciclovir-resistant isolate [9] . These data suggest that K449 and Y469 are not related to antiviral resistance and most likely represent UL97 mutations 
